Clinical Trial Update: Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age [Phase 3]

View source ↗

Summary

Phase 3 trial updating immunogenicity, safety, and tolerability of adjuvanted and non-adjuvanted swine-origin H1N1 influenza vaccine in healthy adults 18+.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pandemic Influenza

Drugs mentioned

• A/H1N1 swine-origin influenza vaccine (adjuvanted and non-adjuvanted)

Snippet

Sponsor: Novartis Vaccines | Conditions: Pandemic Influenza | Phase 3 | Status: COMPLETED